Abstract Transforming growth factor-β (TGF-β) is a potent pleiotropic cytokine that regulates mammalian development, differentiation, and homeostasis in essentially all cell types and tissues. TGF-β normally exerts anticancer activities by prohibiting cell proliferation and by creating cell microenvironments that inhibit cell motility, invasion, and metastasis. However, accumulating evidence indicates that the process of tumorigenesis, particularly that associated with metastatic progression, confers TGF-β with oncogenic activities, a functional switch known as the "TGF-β paradox." The molecular determinants governing the TGF-β paradox are complex and represent an intense area of investigation by researchers in academic and industrial settings. Recent findings link genetic and epigenetic events in mediating the acquisition of oncogenic activity by TGF-β, as do aberrant alterations within tumor microenvironments. These events coalesce to enable TGF-β to direct metastatic progression via the stimulation of epithelial-mesenchymal transition (EMT), which permits carcinoma cells to abandon polarized epithelial phenotypes in favor of apolar mesenchymal-like phenotypes. Attempts to deconstruct the EMT process induced by TGF-β have identified numerous signaling molecules, transcription factors, and microRNAs operant in mediating the initiation and resolution of this complex transdifferentiation event. In addition to its ability to enhance carcinoma cell invasion and metastasis, EMT also endows transitioned cells with stem-like properties, including the acquisition of selfrenewal and tumor-initiating capabilities coupled to chemoresistance. Here, we review recent findings that delineate the pathophysiological mechanisms whereby EMT stimulated by TGF-β promotes metastatic progression and disease recurrence in human carcinomas.
Introduction
Transforming growth factor-β (TGF-β) is a ubiquitously expressed cytokine that regulates an assortment of biological activities in essentially all cell types and tissues. In addition to its role in regulating cell development, differentiation, and survival, TGF-β inhibits the proliferation of epithelial, endothelial, and hematopoietic cell lineages (Blobe et al. 2000; Massague 2008; Tian et al. 2011) . Interestingly, resistance to TGF-β-mediated cytostasis is a hallmark of neoplastic transformation, which ultimately transforms the signals produced by this cytokine into oncogenic activities, particularly enhanced cancer cell invasion and metastasis. This conversion in TGF-β function is known as the "TGF-β paradox" (Rahimi and Leof 2007; Schiemann 2007; Tian and Schiemann 2009 ) and underlies the adverse prognosis associated with elevated TGF-β levels in developing carcinomas, including their acquisition of epithelial-mesenchymal transition (EMT), metastatic, and chemoresistant phenotypes (Taylor et al. 2010; Tian and Schiemann 2009; Wendt et al. 2009a ). The molecular mechanisms whereby TGF-β suppresses tumor formation remain to be fully elucidated, as does the manner in which this cytokine promotes the progression of latestage carcinomas. Historically, investigations into TGF-β action have applied "cell-centric" approaches to interrogate the TGF-β paradox by means of monitoring the differential expression of gene transcripts, proteins, and microRNAs that exist between normal and malignant cells as a potential means to explain the dichotomous functions of TGF-β. Although enormous strides have been made through these analyses (Kang et al. 2003; Minn et al. 2005; Zavadil et al. 2001) , the results have collectively failed both to explain the contradictory nature of TGF-β and to recapitulate accurately the TGF-β paradox in experimental settings. Because of these limitations, recent studies have begun to investigate the impact that dynamic alterations in carcinoma microenvironments play in dictating the behaviors of TGF-β. Indeed, numerous findings point to a prominent role of EMT in manifesting the TGF-β paradox and its ability to couple TGF-β to metastatic progression in human carcinomas. Here, we review recent results that directly impact our understanding of the role of TGF-β in mediating the initiation and resolution of EMT, and the way that these events underlie the pathophysiology of TGF-β in human malignancies.
TGF-β signaling
Mammals express three genetically distinct TGF-β ligands (e.g., TGF-βs 1-3) whose mature and biologically active forms are~97% identical and exhibit virtually indistinguishable actions in vitro (Blobe et al. 2000 , Massague 1998 ). Individual TGF-β ligands are expressed spatiotemporally during embryogenesis and tissue morphogenesis, events contributing to the vast array of diverse and nonredundant phenotypes displayed by mice lacking distinct TGF-β isoforms (Chang et al. 2002) . TGF-β signaling commences by its binding to three high-affinity receptors, TGF-β type I (TβR-I), type II (TβR-II), and type III (TβR-III or betaglycan) receptors. When expressed, TβR-III is the most abundant TGF-β receptor present on the cell surface where it (1) functions as an accessory receptor that binds and modulates TGF-β function in responsive cells and (2) mediates the tumor-suppressing activities of TGF-β in tissues of the breast, ovary, prostate, lung, pancreas, kidney, and endometrium (Gatza et al. 2010) . Although TβR-III lacks intrinsic enzymatic activity, TβR-I and TβR-II both harbor Ser/Thr protein kinases in their cytoplasmic domains that initiate intracellular signaling (Feng and Derynck 2005; Massague and Gomis 2006; Shi and Massague 2003) . The binding of TGF-β to TβR-II enables this polypeptide to transphosphorylate and activate TβR-I, which subsequently binds, phosphorylates, and stimulates the latent transcription factors, Smad2 and Smad3 (Feng and Derynck 2005; Massague and Gomis 2006; Shi and Massague 2003) . Phosphorylated Smad2/3 rapidly form high order complexes with the common Smad, Smad4, which enables the resulting heterotrimeric complexes to take up residence in the nucleus where they regulate transcription in a gene-and cell-specific manner (Feng and Derynck 2005; Massague and Gomis 2006; Shi and Massague 2003) . Changes in cell behavior regulated by the activation of Smad2/3 are referred to as "canonical TGF-β signaling", and these events are modulated in all subcellular compartments by numerous effector molecules.
In addition to its activation of canonical Smad2/3 signaling, TGF-β also couples to a variety of noncanonical effector molecules (i.e., Smad2/3-independent), including (1) the mitogen-activated protein (MAP) kinases, ERK1/2, p38MAPK, and JNK; (2) the cell survival mediators, PI3K, AKT1/2, and mTOR; (3) the inflammation mediators, NF-κB, cyclooxygenase-2 (Cox-2), and prostaglandins; (4) the small GTP-binding proteins, Ras, RhoA (Ras homolog gene family, member A), Rac1, and Cdc42; and (5) the nonreceptor protein tyrosine kinases, Src, FAK, and Abl (Kang et al. 2009; Moustakas and Heldin 2005; Parvani et al. 2011) . Interestingly, recent findings indicate that the coupling of TGF-β to its noncanonical effectors appears inappropriately amplified in metastatic cancer cells, thereby generating a signaling imbalance that overrides and/or dampens the tumor-suppressing messages transduced by Smad2/3 in human tumors (Wendt et al. 2009b) . Figure 1 depicts the interactome of noncanonical effector molecules targeted by TGF-β during EMT and metastatic progression. Unfortunately, the way that these noncanonical effectors are precisely activated by TGF-β in normal and malignant cells remains to be determined definitively, as does the manner in which these pathways become dysregulated and magnified during the acquisition of metastatic phenotypes by cancer cells. These relationships and their regulation by tumor microenvironments during the initiation of EMT and metastatic progression driven by TGF-β are discussed below.
Epithelial-mesenchymal transitions
Definition and classical EMT phenotypes EMT is a normal physiological process that is essential for embryogenesis and tissue morphogenesis and for tissue remodeling and repair during wound healing (Wendt et al. 2009a ). However, pathological EMT is increasingly recog-nized to play an important role during the development of human diseases, including chronic inflammation, fibrosis, rheumatoid arthritis, and cancer invasion and metastasis (Micalizzi et al. 2010a; Taylor et al. 2010; Thiery et al. 2009 ). EMT was first described almost a century ago with the observation that epithelial cells in chick embryos acquire mesenchymal-like features (Thiery 2002) , an event officially recognized as being a discrete physiological process by Greenberg and Hay in 1982 (Greenburg and Hay 1982) . The ability of TGF-β to induce EMT was initially described by Derynck and colleagues in 1994 (Miettinen et al. 1994) . During the intervening years since this important discovery, the findings of numerous studies have coalesced in establishing TGF-β as a master regulator of the initiation and resolution of EMT under a variety of pathophysiological contexts (Taylor et al. 2010; Wendt et al. 2009a) . Typically, differentiated epithelium is composed of a single layer of polarized epithelial cells that possess an apical and basolateral orientation and of an actin cytoskeleton organized into defined "cobblestones" attributable to the concentration of polymerized actin fibers at cell-cell junctions. The EMT process occurs when fully differentiated epithelial cells undergo a transdifferentiation process that gives rise to their bearing fibroblastoid-like phenotypes (Micalizzi et al. 2010a; Taylor et al. 2010; Thiery et al. 2009 ). Additionally, transdifferentiating epithelial cells exhibit a variety of common molecular features, including (1) the downregulated expression of polarized epithelial cell markers (e.g., E-cadherin [E-cad], zonula occludens-1 [ZO-1], β4 integrin, and cytokeratin 19); (2) rearrangements of the actin, intermediate filaments, and myosin cytoskeletal systems; (3) redistribution of intracellular organelles; and (4) the upregulated expression of mesenchymal cell markers (e.g., N-cadherin, vimentin, and α-smooth muscle actin) and invasive factors (e.g., matrix metalloproteinases [MMPs] and extracellular matrix [ECM] molecules; Micalizzi et al. 2010a; Taylor et al. 2010; Thiery et al. 2009 ). Figure 2 depicts these events and highlights many of the most wellestablished and best characterized markers of EMT, including (1) E-and N-cadherins (Bhowmick et al. 2001a; Hazan et al. 2000; Miettinen et al. 1994) ; (2) vimentin (Grunert et al. 2003; Mendez et al. 2010) ; (3) fibronectin (Ignotz and Massague 1986) ; (4) α-smooth muscle actin (Masszi et al. 2003; Yazhou et al. 2004 ); (5) MMPs (Duivenvoorden et al. 1999 ; E.S. Lee et al. 2008 ); and (6) β3 integrin (Galliher and Schiemann 2006; Wendt and Schiemann 2009 ).
An important feature of the EMT process manifests through the disintegration and disassembly of epithelial cell-cell adhesion complexes, including desmosomes and gap, tight, and adherens junctions that function in maintaining epithelial cell polarity and in restricting cell motility (Cavallaro and Christofori 2004; Christofori 2003) . Inactivating the expression and activity of these junctional complexes enables transitioning epithelial cells to abandon their immotile and polarized architectures and to assume highly motile and apolar architectures characteristic of mesenchymal-like cells (Fig. 2) . For example, tight junctions arise from the collective actions of claudins, occludins, and junctional adhesion molecules, which are connected to the actin cytoskeleton via the scaffold proteins ZO-1, -2, and −3 (Ebnet et al. 2004; Schneeberger and Lynch 2004) . Par6 (partitioning-defective 6) plays an essential role in overseeing (1) the formation of tight junctions; (2) the generation of apical-basolateral polarity; and (3) the initiation of polarized cell migration (Bose and Wrana 2006) . Par6 also interacts physically with TGF-β receptors and can be phosphorylated by TβR-II, leading to Fig. 1 Epithelial-mesenchymal transition (EMT) signaling network and transcriptome regulated by TGF-β (red ellipses genes whose expression is increased by TGF-β during EMT, green ellipses genes whose expression is decreased by TGF-β during EMT, orange ellipses increased enzymatic activity stimulated by TGF-β during EMT, lines between nodes describe the interaction or transactivation between these molecules during EMT) the formation of Par6:Smurf1 complexes that promote the ubiquitination and degradation of RhoA (Ozdamar et al. 2005) . These events culminate in the dissolution of tight junctions during EMT stimulated by TGF-β. Moreover, uncoupling the ability of TGF-β to regulate Par6 activity is sufficient to prevent EMT induced by TGF-β (Ozdamar et al. 2005 ) and its stimulation of breast cancer metastasis in mice (Viloria-Petit et al. 2009 ).
In contrast to tight junctions, adherens-based junctional complexes are comprised primarily of the transmembrane protein, epithelial cadherin (E-cad), which connects to the actin cytoskeleton via α-and β-catenins (Niessen 2007) . TGF-β stimulation of EMT inactivates E-cad function by repressing the synthesis of E-cad transcripts or by delocalizing and internalizing E-cad proteins from the cell membrane, an event coupled to a loss of Rac1 activity (Takaishi et al. 1997) . The dissolution of cell-cell contacts accompanies the formation of prominent actin filaments and the appearance of fibroblastoid-like phenotypes in transitioning epithelial cells. The ability of TGF-β to remodel the actin cytoskeleton arises through the activation of RhoA (Bhowmick et al. 2001a; Ridley and Hall 1992) , which together with diminished cell adhesion elicits cell migration and invasion. TGF-β also modulates the adhesion of transitioning epithelial cells by stimulating their expression of MMPs, while simultaneously inhibiting that of their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs); this collectively leads to the degradation of various basement membrane constituents such as collagen IV and laminin (Duivenvoorden et al. 1999) . Collectively, these phenotypic and morphologic changes conspire to transform immobile multicellular epithelial sheets into highly motile, independent units that are poised for invasion and metastasis.
Classifying EMT subtypes
The process of EMT has recently been categorized into three distinct subtypes based the biological settings and contexts in which the EMT event is activated. Importantly, the generic features attributed to EMT are readily observed in all of the three major EMT subtypes. For instance, type 1 EMT is activated during embryogenesis and tissue morphogenesis, whereas type 2 EMT is initiated during tissue regeneration, wound healing, and inflammation-driven fibrosis. Finally, type 3 EMT is employed by carcinoma cells during their acquisition of invasive and metastatic phenotypes (Kalluri and Weinberg 2009 ). In the following sections, we highlight evidence linking TGF-β to the regulation of individual EMT subtypes, particularly that of type 3 EMT during metastatic progression stimulated by TGF-β. (1) E-cadherin, the primary component of adherens junctions. During EMT, TGF-β represses E-cadherin expression and induces its internalization from the plasma membrane (Miettinen et al. 1994) . (2) N-cadherin, an adhesion molecule that promotes cellular migration (Hazan et al. 2000) . EMT stimulated by TGF-β is associated with increased expression of N-cadherin (Bhowmick et al. 2001a) . (3) Vimentin, an intermediate filament protein that is expressed in all primitive cell types, but not in differentiated epithelial cells. Vimentin might function to drive EMT programs (Mendez et al. 2010) and also serves as a canonical marker for detecting transdifferentiated mesenchymal cell types (Grunert et al. 2003) . (4) Fibronectin, a critical extracellular matrix (ECM) component whose elevated production by cancer cells is classically associated with EMT programs. TGF-β is a potent inducer of fibronectin production and its deposition into the ECM (Ignotz and Massague 1986) . (5) α-Smooth muscle actin (α-SMA), a major component of contractile microfilaments and a canonical marker for detecting myofibroblasts. TGF-β stimulation of EMT elicits α-SMA expression (Masszi et al. 2003) , which strongly associates with increased tumor invasion and with decreased patient survival (Yazhou et al. 2004) . (6) Matrix metalloproteinases (MMPs). These enzymes proteolytically degrade basement membranes to allow primary tumor cells to invade the surrounding tissue and intrasvasate into tumor-associated vasculature. Whereas several MMPs are induced during EMT, MMP-9 is a wellestablished target of TGF-β signaling (Duivenvoorden et al. 1999 ; E.S. Lee et al. 2008) . (7) β3 Integrin, a transmembrane protein that physically links the ECM to intracellular signaling systems and the cytoskeleton via focal adhesion complexes. β3 Integrin is rapidly and robustly upregulated by TGF-β and interacts physically with TGF-β type II receptor (TβR-II) via a FAK-dependent mechanism (Galliher and Schiemann 2006; Wendt and Schiemann 2009) Type 1 EMT Type 1 EMT is synonymous with developmental EMT, and as such, this EMT subtype occurs during embryogenesis to facilitate the faithful synthesis of organs and tissues. Initiation of type 1 EMT promotes gastrulation and the subsequent formation of ectodermal, mesodermal, and endodermal tissues from the invaginating primitive streak (Micalizzi and Ford 2009; Yang and Weinberg 2008) . In conjunction with the Wnt signaling pathway, primitive streak cells readily undergo EMT when stimulated by the TGF-β superfamily members, Nodal, Vg1 (a Xenopus laevis homolog of human TGF-beta), and bone morphogenetic protein-2 (Chea et al. 2005; Conlon et al. 1994; Raible 2006; Skromne and Stern 2001; Zhou et al. 1993) . Type 1 EMT is also initiated during neurulation to facilitate neural tube formation during spinal and cerebral development, and again by neural crest cells to generate the adrenal medulla and the skeletal and peripheral nervous systems (SaukaSpengler and Bronner-Fraser 2008) . Additional insights associating TGF-β signaling to developmental EMT programs have been gleaned by genetically engineering mice to lack the expression of individual TGF-β isoforms and their receptors. For example, homozygous deletion of TGF-β2 elicits perinatal lethality attributable to multiple defects in the initiation of type 1 EMT during organogenesis and tissue morphogenesis, particularly that linked to atrioventricular valve formation by transitioned endocardial cells (Sanford et al. 1997) . Likewise, the disruption of the TGF-β3 locus also produces perinatal lethality resulting from defective type 1 EMT, which occurs during lung and palate development (Kaartinen et al. 1995) . Finally, the expression and activity of TβR-III are essential for TGF-β to stimulate type 1 EMT necessary for normal heart and secondary palate formation (Brown et al. 1999; Nakajima et al. 2007 ).
Type 2 EMT
Type 2 EMT plays an essential role in governing tissue homeostasis via its ability to induce the healing and remodeling of wounded tissues. Unlike type I EMT, transdifferentiation initiated by type 2 EMT is driven by inflammatory reactions, whose termination is sufficient to resolve the EMT event following wound repair (Kalluri and Weinberg 2009 ). The series of events that underlie type 2 EMT during wound healing and tissue remodeling are highly complex and require coordinated interactions between multiple cell types, such as fibroblasts and endothelial and immune cells, to facilitate the re-epithelialization of damaged epithelium. TGF-β plays a key role in mediating these events, doing so in part by promoting myofibroblast activation and differentiation coupled to the ECM remodeling necessary for tissue repair (Taylor et al. 2010) . Interestingly, chronic inflammatory reactions can trigger a dysregulated type 2 EMT response that engenders the formation of a variety of fibroproliferative disorders, particularly in the lung, liver, kidney, and retina (Wynn 2007; Wynn 2008) . Similarly, the inhibition of collagen cross-linking during mammary fibrosis significantly reduces breast cancer metastasis in mice (Levental et al. 2009 ), findings consistent with the notion that desmoplastic and fibrotic reactions enhance the incidence of mammary tumorigenesis (Boyd et al. 2007 ). Thus, the chemotherapeutic targeting of the TGF-β signaling system might abrogate neoplastic progression by simultaneously inactivating the deleterious activities associated with pathologic type 2 and type 3 EMTs (see below).
Type 3 EMT
Type 3 EMT is synonymous with oncogenic EMT and is essential in facilitating the acquisition of invasive and metastatic phenotypes by developing neoplasms (Micalizzi et al. 2010a; Taylor et al. 2010; Thiery et al. 2009 ). Oncogenic EMTs are readily distinguished from their normal counterparts, because these events arise in malignant cells that harbor a host of genetic and epigenetic abnormalities that coalesce in hijacking the EMT process during metastatic dissemination. Importantly, EMT stimulated by TGF-β has been linked to the selection and expansion of cancer stem cells (CSCs; Ben-Porath et al. 2008; Mani et al. 2008; Morel et al. 2008; Shipitsin et al. 2007 ) and, by extension, to the development of chemoresistance and disease recurrence (Frank et al. 2010; Singh and Settleman 2010) . Even more remarkably, recent findings have implicated EMT as the molecular determinant that manifests the TGF-β paradox and the conversion of TGF-β function from that of a tumor suppressor to an inducer of metastatic progression. In the succeeding sections, we present evidence linking EMT to the acquisition of oncogenic TGF-β signaling and provide an overview of the way that TGF-β stimulates type 3 EMT in developing neoplasms.
TGF-β paradox
The initial framework underlying the TGF-β paradox began nearly 30 years ago when TGF-β was originally defined by its ability to promote the morphological transformation and anchorage-independent growth of normal rat kidney fibroblasts (NRK-49 cells; Moses et al. 1981; Roberts et al. 1981) . Shortly thereafter, opposing findings obtained in epithelial cells established TGF-β as a potent and powerful inhibitor of cell proliferation (Carr et al. 1986 ). Thus, TGF-β stimulates the growth of mesenchymal cell lineages but inhibits that of epithelial cell lineages. Interestingly, studies from this same era demonstrated that transformed cells secrete 40-fold more TGF-β as compared with their nontransformed counterparts (Anzano et al. 1985) . This important observation strongly suggested that cellular transformation accompanies a loss in the tumorsuppressing functions of TGF-β. The merits of this supposition were quickly translated and verified in mouse models of tumorigenesis. For instance, implanting slowrelease TGF-β pellets in female mice reversibly inhibits mammary gland growth and morphogenesis (Silberstein and Daniel 1987) . In contrast, inoculation with neutralizing TGF-β antibodies enhances the ability of natural killer cells to eradicate breast cancer development and progression in mice (Arteaga et al. 1993) . A specific role for TGF-β in promoting metastasis was established by the conditional expression of constitutively active TGF-β1, which selectively enhances the pulmonary metastasis of mammary tumors without altering their growth and proliferation (Muraoka-Cooket al. 2004 ). Likewise, transgenic expression of constitutively active TGF-β1 in mouse keratinocytes promotes their proliferation and eventual progression to spindle cell carcinoma in a chemical carcinogenesis model of skin cancer Fowlis et al. 1996) . More recently, conditional deletion of TβR-I expression in the oral cavity of mice has been observed to facilitate carcinogen-induced tumor formation in part via constitutive PI3K/AKT activity (Bian et al. 2009 ), whereas the combination of TβR-I haploinsufficiency with an Apc( Min/+ ) background produces twice as many intestinal tumors as compared with wild-type mice (Zeng et al. 2009 ). Collectively, these and other findings establish a paradigm whereby TGF-β potently inhibits tumor initiation and the development of early-stage carcinomas but enthusiastically drives the metastatic progression of late-stage carcinomas.
In addition to its ability to induce cytostasis in epithelial cells, TGF-β also governs the behaviors of adjacent fibroblasts and their synthesis and secretion of paracrine factors and ECM molecules that collectively suppress carcinoma development. For instance, the targeted deletion of TβR-II in mammary carcinoma cells facilitates the inappropriate activation of two distinct paracrine signaling axes, i.e., SDF-1:CXCR4 and CXCL5:CXCR2, which leads to the recruitment of immature GR1 +
CD11b
+ myeloid cells that drive breast cancer metastasis by inhibiting host tumor immunosurveillance and by inducing MMP expression . Likewise, rendering fibroblasts deficient in TβR-II expression elicits prostate intraepithelial neoplasia and invasive carcinoma of the forestomach resulting from disruptions in tumor-suppressing paracrine signaling networks (Bhowmick et al. 2004) . Moreover, similar inactivation of TβR-II in mammary fibroblasts greatly exaggerates the growth and invasion of breast cancer cells simultaneously engrafted under the renal capsule. The proliferation-promoting activities of TβR-IIdeficient fibroblasts derive from their upregulated expression of TGF-α, MSP (macrophage-stimulating protein), and HGF (hepatocyte growth factor; Cheng et al. 2005) . Finally, the genetic inactivation of Smad4 in T cells elicits carcinoma formation within the gastrointestinal tract (e.g., colon, rectum, intestine, and stomach) attributable to aberrant stromal expansion and signaling (Kim et al. 2006) . Collectively, these findings highlight the paradoxical activities of TGF-β in normal and malignant cells and, in doing so, point to the potential difficulties in developing effective therapies capable of predictably circumventing the context-and stage-specific behaviors of this cytokine in neoplastic tissues.
Mechanisms underlying type 3 EMT driven by TGF-β TGF-β and transcriptional regulators of EMT Attempts to deconstruct the EMT process have identified a variety of transcription factors that mediate essential functions in activating the "EMT transcriptome" necessary to bring about the epithelial transdifferentiation process (Table 1) . Indeed, heterologous expression of the transcription factor Twist, which fulfils a critical role during mesoderm development (Leptin 1991) , results in the initiation of the EMT program. Consistent with a role for EMT in driving carcinoma metastasis, rendering metastatic breast cancer cells deficient in Twist expression abrogates their ability to metastasize (Yang et al. 2004) . Snail-1 is similarly required during mesoderm development and its expression readily represses that of E-cad (Cano et al. 2000) . More recently, Snail-2 (also know as Slug) has been identified as a downstream effector of Twist, one that plays an essential role in facilitating Twist-mediated downregulation of E-cad (Casas et al. 2011; Mani et al. 2008 ). In addition to inducing the expression of Twist (Allington et al. 2009; Lee et al. 2008; Mani et al. 2008) , TGF-β is also coupled to the expression of high mobility group A2 (HMGA2), leading to the robust downregulation of E-cad expression concomitant with the induction of Snail-1, Snail-2, and Twist (Thuault et al. 2006) . Similarly, the findings of several studies support the notion that E-cad plays an active role in maintaining differentiated and polarized epithelial phenotypes, and indeed, E-cad deficiency is sufficient to elicit a robust EMT in mammary epithelial cells (Battula et al. 2010; Mani et al. 2008; Onder et al. 2008; Taube et al. 2010) . Interestingly, recent evidence suggests that the expression and activity of these EMT transcription factors elicits a "feed forward" response coupled to increased autocrine TGF-β production and signaling (Taube et al. 2010) . Elucidation of the molecular mechanisms operant in mediating autocrine TGF-β signaling and its stabilization of the EMT process might shed new light on and provide a better understanding of the differences between physiological (i.e., types 1 and 2) and pathological (type 3) EMT. Indeed, prolonged induction of EMT results in the recruitment of DNA methyltransferases and chromatin remodeling enzymes to the promoters of EMT-regulated genes targeted by TGF-β, including estrogen receptor-α and E-cad (Dumont et al. 2008) . Moreover, the inhibition of canonical Smad2 signaling, either by the inactivation of its expression or by the overexpression of the inhibitory Smad, Smad7, is sufficient to induce a mesenchymal-epithelial transition (MET) initiated by the loss of epigenetic silencing of epithelial-associated genes (Papageorgis et al. 2010 ). Collectively, these findings provide an initial framework to begin delineating the sequential nature of events associated with EMT induced by TGF-β and its ability to dictate epigenetic silencing as a means to stabilize and maintain oncogenic EMT programs.
TGF-β and microRNAs
Recent evidence has associated the expression of microRNAs with the initiation of the TGF-β paradox and its promotion of oncogenic TGF-β signaling (Table 1) . For instance, EMT induced by TGF-β downregulates the expression of the microRNA-200 (miR-200) family, which facilitates the expression of ZEB1/2 (zinc finger E-boxbinding homeobox 1/2) and their repression of E-cad expression in transitioning cells (Gregory et al. 2008; Korpal et al. 2008) . Moreover, the absence of miR-200 expression has predictive value in identifying highly invasive and metastatic carcinomas (Burk et al. 2008; Singh et al. 2008) . Interestingly, loss of miR-220c expression has been linked to inactivation of p53 function, an event coupled to the acquisition of EMT and stem-cell-like phenotypes (Chang et al. 2011) . Similarly, we have recently identified c-Abl as a potent suppressor of EMT stimulated by TGF-β (Allington et al. 2009 ), an event that occurs via c-Abl-mediated reactivation of p53 expression and its induction of p21 (T.M.A. and W.P.S., unpublished). Likewise, elevated ZEB1/2 expression and the accompanying EMT are sufficient to overcome senescence induced by either p53 activation or epidermal growth factor receptor (EGFR) overexpression (Ohashi et al. 2010 ). In addition to its regulation of the miR-220 family of microRNAs, TGF-β also stimulates the processing of primary miR-21 transcripts into their pre-miR-21 counterparts, an event requiring the formation of Smad2/3:DROSHA complexes. Interestingly, these miR maturation events occur normally Tiam1 (T-cell lymphoma invasion and metastasis 1; Cottonham et al. 2010; Davis et al. 2008; Zavadil et al. 2007) in Smad4-deficient cells (Davis et al. 2008) , thereby identifying a novel bifurcation in the canonical TGF-β signaling system that couples specifically to miRprocessing events. TGF-β stimulation of miR-21 and miR-31 expression serve in promoting EMT programs coupled to cell migration and invasion, presumably via the downregulated expression of the guanine exchange factor, Tiam1 (T-cell lymphoma invasion and metastasis 1; Cottonham et al. 2010; Zavadil et al. 2007 ). The induction of miR-155 expression by TGF-β proceeds through a Smad4-dependent pathway and is necessary in mediating downregulated RhoA expression during EMT reactions (Kong et al. 2008) . Finally, Myc amplification has recently been shown to induce miR-9 expression, which enhances breast cancer metastasis by downregulating E-cad expression . Although a direct role for TGF-β in regulating these events has not been examined, these findings nonetheless might provide new insights into the way that aberrant Myc expression overrides the cytostatic actions of TGF-β (Alexandrow et al. 1995; Chen et al. 2001) . Figure 1 depicts the relationship between various microRNAs and TGF-β effector molecules operant in eliciting EMT programs.
Impact of integrins during EMT induced by TGF-β
As discussed above, variations in the composition of the ECM can elicit profound alterations in the way that normal and malignant cells respond to TGF-β. Mechanistically, these disparate functions of TGF-β have been linked to the expression and activity originating from integrins. For example, we have observed TβR-II to interact physically with β3 integrin following its activation by vitronectin or following its elevated expression, which arises during EMT induced by TGF-β (Galliher and Schiemann 2006; Galliher and Schiemann 2007; Galliher-Beckley and Schiemann 2008) . Additionally, the formation of β3 integrin:TβR-II complexes is critically dependent upon the expression and activity of FAK, such that depleting FAK expression disrupts the interaction between these receptors and markedly reduces the ability of TGF-β to stimulate breast cancer invasion and metastasis (Wendt and Schiemann 2009 ). Interestingly, the FAK effector, p130Cas, has been found to bind and sequester Smad3, thereby preventing its phosphorylation by TβR-I and its subsequent translocation into the nucleus . Similarly, we have observed that elevated p130Cas expression marks metastatic progression and distorts the delicate balance between canonical and noncanonical TGF-β signaling systems in metastatic breast cancers (Wendt et al. 2009b ). Indeed, rendering metastatic breast cancer cells deficient in p130Cas expression drastically reduces breast cancer development and progression stimulated by TGF-β (Wendt et al. 2009b) , presumably by enhancing the sensitivity of p130Cas-deficient cells to apoptotic stimuli (Cabodi et al. 2006) . Interestingly, TβR-II also interacts physically with β1 integrin (Galliher and Schiemann 2006) , which is required for TGF-β to induce EMT and activate p38 MAPK (Bhowmick et al. 2001b) . Taken together, these findings highlight the direct influence that integrins and focal adhesion complexes have in promoting EMT and metastatic progression stimulated by TGF-β. Additional insights into the role of integrins in regulating normal and malignant cell responses to TGF-β have been gleaned through the use of three-dimensional (3D)-organotypic culture systems. For instance, the inactivation of β4 integrin function in normal mammary epithelial cells elicits their formation of dysmorphic acinar structures reminiscent of those produced by malignant mammary epithelial cells (Weaver et al. 2002) . Conversely, the inactivation of β1 integrin function in breast cancer cells elicits their formation of spherical acinar structures reminiscent of normal mammary epithelial cells (Weaver et al. 1997 ). More recently, collagen has been incorporated within these 3D-organotypic cultures as a means to better recapitulate the microenvironmental compliance experienced by palpable primary tumors and to initiate mechanotransduction pathways coupled to integrin activation (Paszek et al. 2005) . In undertaking similar analyses, we have observed compliant 3D-organotypic cultures to be sufficient in restoring the cytostatic activities of TGF-β in metastatic breast cancer cells that are normally completely resistant to the antiproliferative activities of TGF-β in traditional twodimensional culture systems (Allington et al. 2009; Taylor et al. 2011) . Importantly, the inclusion of type I collagen in these 3D-organotypic cultures to increase their rigidity (i.e., decreased compliance) and initiate mechanotransduction has been observed to dose-dependently uncouple TGF-β from the regulation of cell cycle progression (Allington et al. 2009 ). Conversely, the treatment of developing organoids with the small molecule TβR-I inhibitor (TβR-I Inhibitor II) stimulates the growth of 4T1 cells in compliant 3D-organotypic cultures, wherein TGF-β functions as a tumor suppressor. However, administration of this same pharmacologic regimen to rigid 3D-organotypic cultures, wherein TGF-β functions as a tumor promoter, greatly inhibits the growth of the resultant 4T1 organoids , thereby validating the first in vitro system that recapitulates the TGF-β paradox solely by modulating the tension sensed by malignant mammary epithelial cells. Importantly, the expression and activity of lysyl oxidase stimulated by TGF-β contributes to its acquisition of oncogenic behavior and the induction of EMT in normal and malignant mammary epithelial cells . Oncogenic TGF-β signaling brought about by mechanotransduction is partially neutralized by rendering breast cancer cells deficient in lysyl oxidase expression, which enhances E-cad expression and activity in developing organoids . Similarly, an increase in ECM rigidity not only induces dramatic differences in cell proliferation, but also suppresses E-cad expression by promoting EMT programs (Tilghman et al. 2010) , presumably via rigidity-induced TGF-β synthesis and autocrine signaling coupled to the integrin-mediated activation of latent TGF-β complexes Wipff et al. 2007) . Recently, the initiation of MET programs and the elevated expression of E-cad have been observed to promote the metastatic outgrowth of disseminated breast cancer cells in the lungs of mice (Chao et al. 2010; Dykxhoorn et al. 2009 ). Somewhat paradoxically, E-cad expression has also been shown to normalize acinar morphology and growth (Wang et al. 2002) , presumably via heterotypic binding to and the regulation of β1 integrin expression (Whittard et al. 2002; Wu et al. 2006; . As a means to explain these contrasting findings, we have recently found that the heterotypic binding of Ecad to β1 integrin suppresses its expression and inhibits the initiation of metastatic outgrowth by breast micrometastases. Moreover, the conversion from dormancy to proliferative programs capable of supporting metastatic outgrowth requires a transient EMT event, which downregulates E-cad expression and upregulates that of β1 integrin necessary for micrometastatic outgrowth (M.K.W. and W.P.S., unpublished). Collectively, these studies provide novel insights into the role of mechanotransduction in mediating oncogenic TGF-β signaling and its coupling to type 3 EMT during distinct stages of the metastatic cascade (Drake et al. 2009; Wendt et al. 2010 ).
Impact of growth factor receptors during EMT induced by TGF-β As mentioned above, recent advancements in the use of 3D-organotypic cultures have shed new light onto the importance of cell and tumor microenvironments in regulating the TGF-β stimulation of EMT. In a similar avenue of research, studies are now investigating the specific impact played by other tumor-derived growth factors and chemokines in coupling TGF-β to EMT programs. For instance, the expression and activity of Cox-2 are essential in facilitating TGF-β stimulation of EMT in normal and malignant mammary epithelial cells (Neil et al. 2008; Tian and Schiemann 2010) . Importantly, the coupling of TGF-β to Cox-2 expression is increased synergistically by costimulation with EGF and its activation of MAP kinases (Saha et al. 1999) . Interestingly, TGF-β can transactivate EGFR via a Src-dependent pathway coupled to the activation of TACE/ADAM17 (TNF-α-converting enzyme) and its cleavage of EGF-like ligands (Murillo et al. 2005; S. E. Wang et al. 2009 ). In agreement, two-photon intravital imaging analyses have assisted in identifying a paracrine signaling axis comprised of carcinoma-cell-derived colonystimulating factor-1 (CSF-1) and macrophage-derived EGF, which facilitates tumor cell migration and invasion (Patsialou et al. 2009; Wang et al. 2007; Wyckoff et al. 2004 ). Importantly, TGF-β plays an essential role in establishing this paracrine signaling network through its ability to upregulate CSF-1 receptor expression (Patsialou et al. 2009 ). EGFR also activates the transcription factor STAT3 (signal transducer and activator of transcription-3), which induces the Twist expression necessary to induce autocrine TGF-β signaling (Lo et al. 2007) . We have recently demonstrated that TGF-β stimulation of EMT confers invasive activity to EGFR in part by (1) stabilizing its expression at the cell surface, and (2) facilitating its coupling to Src and p38 MAPK (Wendt et al. 2010) . Interestingly, the chronic activation of EMT programs by TGF-β results in the acquisition of resistance to EGFR inhibitors (Barr et al. 2008) . Thus, these findings bolster the notion that transient EMT programs support oncogenic EGFR signaling, whereas those encompassing prolonged EMT programs support "kinase switching" away from EGFR to depend instead upon the actions of fibroblast growth factor receptor or platelet-derived growth factor receptor . Finally, insulin-like growth factor-1 (IGF-1) and its receptor (IGF1R) also induce cell transformation, invasion, and metastasis (Zha and Lackner 2010) , presumably via an EMT event involving the actions of Snail-2, ZEB1/2, and Akt2 (Graham et al. 2008; Irie et al. 2005 ; H.J. Sivakumar et al. 2009 ). Similarly, we find IGF1R expression to render transitioning mammary epithelial cells resistant to apoptotic stimuli when undergoing EMT induced by TGF-β and to play an essential role in mediating cell migration and invasion stimulated by TGF-β (M.T. and W.P.S., unpublished) . Future studies need to determine the molecular mechanisms that elicit kinase switching and the spatiotemporal events that influence their initiation and resolution.
EMT, CSCs, and chemoresistance
EMT and CSCs
Solid tumors are notoriously heterogeneous with respect to their collective morphologies, proliferative indices, genetic lesions, and responsiveness to chemotherapeutic regimens (Visvader 2011) . Housed within this heterogeneous environment lies a subpopulation of CSCs that possess selfrenewal and tumor-initiating properties that give rise to metastatic progression and disease recurrence (Pardal et al. 2003) . Although considerable debate remains regarding the "true" identity of CSCs, several recent studies have identified a variety of proteins that serve to mark tumorinitiating cells (Table 2). For example, CD44   +   /CD24   -/low   ,  CD29 hi /CD24 med , or aldehyde dehydrogenase 1 (ALDH1) can differentiate breast CSCs from those lacking tumorinitiating properties (Al-Hajj et al. 2003; Ginestier et al. 2007) , whereas detection of the expression of CD133 has been proposed as a marker for CSCs derived from cancers of the brain, colon, and pancreas (Hermann et al. 2007; O'Brien et al. 2007; Ricci-Vitiani et al. 2007 ). Moreover, cellular efflux of Hoechst stains can visualize a heterogeneous "side-population" of cells enriched in stem cell-like properties (Challen and Little 2006) , as can detection of the expression of EpCAM (epithelial cell adhesion molecule; Munz et al. 2009 ). Importantly, the initiation of EMT programs elicits the selection and expansion of CSCs (BenPorath et al. 2008; Morel et al. 2008; Shipitsin et al. 2007 ), leading to the development of chemoresistant phenotypes and disease recurrence (Creighton et al. 2010; Singh and Settleman 2010; Turley et al. 2008) . Consistent with its function as a master regulator of EMT, TGF-β stimulation of carcinoma cells facilitates the appearance of CSCs in an EMT-dependent manner, suggesting that targeting the TGF-β signaling system can suppress tumor development and progression by inhibiting CSC function. Accordingly, the inactivation of TGF-β signaling in metastatic breast cancers results in a MET that re-establishes a more epithelial-like phenotype in these aggressive cells, whereas elevated TGF-β signatures are associated with metastatic progression and poorer clinical outcomes (Shipitsin et al. 2007 ). Future studies need to determine the impact that might be achieved on tumor development, progression, and recurrence by combining targeted TGF-β chemotherapies with agents capable of selectively targeting CSCs, including the delivery of (1) chemotherapeutic agents coupled to monoclonal antibodies directed at CSC cell-surface markers (Deonarain et al. 2009 ) or (2) pharmaceuticals capable of inactivating CSC drug transporters (Baguley 2010 ).
EMT and chemoresistance
The most common failure in successfully treating cancers is their development of chemoresistance, which typically falls into two major categories: (1) de novo drug resistance, which manifests in the absence of drug selection attributable to a pre-existing phenotype, and (2) acquired drug resistance, which manifests as an adaptive response to drug selection. Mechanistically, acquired drug resistance typically reflects the ability of cells to upregulate their expression of drug efflux transporters or of metabolizing enzymes or to downregulate their drug-induced apoptotic machinery (Gottesman 2002 ). As mentioned above, the initiation of EMT programs underlies disease progression and the emergence of chemoresistance; this has led to the notion that the inactivation of EMT or induction of MET might serve to resensitize carcinoma cells to previously effective treatment regimens (Table 2) . For instance, anti-EGFR inhibitors such as Erlotinib, Gefitinib, or Cetuximab are widely used clinically to treat a variety of human cancers; however, the effectiveness of these drugs is inversely Breast and pancreatic Paclitaxel; Cisplatin; Gemcitabine (Hermann et al. 2007; Hong et al. 2009; Shafee et al. 2008; CD44 + Pancreatic Gemcitabine (Hermann et al. 2007; Hong et al. 2009 ) CD133 + Brain and colon Carboplatin; Paclitaxel; Irinotecan; Temozolomide; Etoposide; Oxaliplatin; 5-FU; Cyclophosphamide (Dylla et al. 2008; Fang et al. 2010; Liu et al. 2006; Ong et al. 2010; Todaro et al. 2007) correlated to the completeness of the EMT program and acquisition of mesenchymal-like phenotypes attained in cancers of the lung, head, and neck (Chin et al. 2008; Frederick et al. 2007; Thomson et al. 2005 Thomson et al. , 2008 Yauch et al. 2005) . Likewise, ZEB1-driven EMT in pancreatic cancers elicits their resistance to Gemcitabine, 5-fluorouricil (5-FU), and Cisplatin (Arumugam et al. 2009 ). Importantly, rendering pancreatic cancer cells deficient in the expression of either ZEB1 or Notch is sufficient to elicit a MET and restore sensitivity to these cytotoxic agents (Arumugam et al. 2009; Z. Wang et al. 2009 ). Similarly, the appearance of acquired resistance reflects the completion of EMT programs in (1) ovarian cancer cells that develop resistance to Paclitaxel (Kajiyama et al. 2007 ); (2) bladder cancer cells that develop resistance to radiotherapy and Cisplatin, an event mediated by ZEB2 (Sayan et al. 2009 ); and (3) luminal breast cancer cells that develop resistance to Paclitaxel, Docetaxel, or Doxorubicin, events mediated by downregulated expression of estrogen receptor-α and upregulated expression of TβR-II (Iseri et al. 2011) . Interestingly, Doxorubicin treatment of breast cancer cells elicits an EMT program sufficient to enhance their metastasis to the lungs and bone in mice. Importantly, administration of the TβR-I antagonist neutralizes the metastasis promoting activities of Doxorubicin (Bandyopadhyay et al. 2010) , suggesting that the ability of cytotoxic agents to induce EMT depends upon the initiation of autocrine TGF-β signaling. Future studies need to determine the overall reliance of EMT induced by TGF-β in mediating acquired resistance to chemotherapeutics and to develop reliable biomarkers capable of typing the function of TGF-β within these developing and progressing neoplasms.
Concluding remarks
The current EMT paradigm states that oncogenic EMT is a metastable and transient process that affords carcinoma cells the ability to escape the confines of the primary tumor and to disseminate throughout the body via the systemic circulation. Similarly, EMT is proficient in generating unique cell populations endowed with self-renewal and stem-like qualities, thereby rendering transitioned cells insensitive to apoptosis, hypoxia, and traditional chemotherapies. At present, the origin of "EMT-competent" carcinoma cells, the location in which they reside within heterogeneous tumor microenvironments, and the extent to which these events can be driven by TGF-β at distinct stages of tumor development remain uncertain. Likewise, whether the EMT phenotype is stable or malleable throughout the evolution of a given tumor and its spatiotemporal susceptibility to the EMT process ( Fig. 3) are still ambiguous. Equally unclear is the precise role played by "EMT-incompetent" cells in (1) supporting the selection, expansion, and dissemination of transitioned carcinoma cells during metastatic progression; (2) enabling transitioned cells to subvert the effects of neoadjuvant chemotherapies; and (3) promoting transitioned cells to escape metastatic dormancy and reinitiate proliferative programs coupled to lethal bouts of disease recurrence. Future studies need to address and fill these gaps in our knowledge, and in doing so, science and medicine might develop the tools necessary to circumvent the TGF-β paradox and its ability to promote EMT, metastatic progression, and disease recurrence in patients harboring metastatic disease. Prolonged exposure of cells to TGF-β or other EMT-initiating factors supports the continued development and expansion of cancer stem cells, which collectively are chemoresistant and underlie disease recurrence. How, when, and where cancer stems cells undergo MET during secondary tumor outgrowth remains to be determined definitively
